As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...